



**Maidstone and
Tunbridge Wells**
NHS Trust

Ref: FOI/GS/ID 7351

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

27 April 2022

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to metastatic non-small cell lung cancer (NSCLC).

You asked:

Q1. In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:

- a. *Afatinib*
- b. *Alectinib*
- c. *Atezolizumab monotherapy*
- d. *Atezolizumab in combination*
- e. *Bevacizumab*
- f. *Brigatinib*
- g. *Capmatenib*
- h. *Ceritinib*
- i. *Crizotinib*
- j. *Dacomitinib*
- k. *Dabrafenib with Trametinib*
- l. *Docetaxel monotherapy*
- m. *Durvalumab*
- n. *Erlotinib*
- o. *Gefitinib*
- p. *Gemcitabine*
- q. *Nintedanib with Docetaxel*
- r. *Nivolumab*
- s. *Osimertinib*
- t. *Paclitaxel*
- u. *Pembrolizumab monotherapy*
- v. *Pembrolizumab in combination*

- w. *Pemetrexed with Carboplatin/Cisplatin*
- x. *Tepotinib*
- y. *Vinorelbine with Cisplatin/Carboplatin*
- z. *Any other SACT*
- aa. *Palliative care only*

Trust response:

Q1.

- a. 2
- b. 5
- c. 0
- d. 0
- e. 0
- f. 1
- g. 0
- h. 0
- i. 2
- j. 0
- k. 0
- l. 1
- m. 1
- n. 0
- o. 2
- p. 0
- q. 0
- r. 0
- s. 8
- t. 0
- u. 8
- v. 17
- w. 2
- x. 0
- y. 2
- z. 5
- aa. 1